Latest News

Timely, factual reporting across artificial intelligence, cybersecurity, companies and markets, EU AI regulation, health and biotech, and climate and energy.

  1. The approval covers adults with active psoriatic arthritis; ILUMYA injections must be administered by a healthcare provider.

  2. The required confirmatory study must track surgery frequency for at least three years in adults and children with recurrent respiratory papillomatosis.

  3. The proposed funding covers land purchases, early enabling work and procurement commitments before construction begins.

  4. OpenAI plans a voluntary implementation in the coming months; the draft lets site operators set training preferences for specific paths.

  5. Mercom counted 120 transactions, with venture funding at $5.4 billion across 79 deals.

  6. Casgevy uses a patient’s blood-forming stem cells, edited outside the body with CRISPR/Cas9 and returned by infusion.

  7. nVent reported $1.515 billion in third-quarter sales for the period ending September 30, up 44% year over year.

  8. BP reported $14.829 billion in third-quarter operating cash flow, including a $0.5 billion adjusted working-capital release.

  9. PRAC will assess the evidence and recommend whether the medicines’ national authorisations should remain unchanged, be amended, suspended or revoked.

  10. Reuters reported Alphabet’s October 29 shares fell 12.6%, with its market value down about $500 billion.